🔗 Share this article

While the US undertakes sweeping revisions to its immunization recommendations, one figure has surfaced unexpectedly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning coronavirus vaccinations throughout the pandemic and has focused upon potential deaths after COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Health officials had intended to unveil sweeping revisions to the pediatric immunization program recently, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of step with many the international standard with insufficient data for benefit. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

Consolidating Power at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing some childhood immunization guidelines in the US so as to align more similar to Denmark's approach, a nation with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or leadership, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for leading the CDER, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Former heads of the center would “grasp legal statutes and the science of drug development”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who ran the center have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just pays attention on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one need to be managed,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the position, which manages in excess of 5,000 employees. “It is a huge administrative position, if you execute it properly,” the former official concluded.

Official Statement and Disputed Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among agency officials on immunizations, a spokesperson responded that the “concerns are based on inaccurate presumptions”.

“Her experience is consistent with the functions of her role,” the representative explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial one-day medication authorization process that allegedly troubled her former heads. “By what process are these drugs being selected for this fast-track system? Who takes the calls?” Dr. Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, track record, Howard have noted. She published a study using unconfirmed crowd-sourced reports to assess the incidence of heart inflammation following Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new government included revising rules for novel immunizations and discontinuing “optional” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccines.

“She is an all-around true believer who commences with her beliefs and works backwards to fit the evidence in a extremely disingenuous, untruthful fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|